



EMMESSAR BIOTECH & NUTRITION LTD

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai -- 400 001
Tel: 022-49738167/68 Email: enquiries@ebnl.org Site: www.ebnl.org
Investors Grievance Email: investors@ebnl.org CIN No. L24110MH1992PLC065942

EBN/2019/S-2475

July 5, 2019

Dept. of Corporate Services
The Stock Exchange, Mumbai
1st floor, New Trading Ring, Rotunda Bldg
Phiroze Jeejebhoy Towers, Dalal Street
Fort, Mumbai – 400 001.
Fax No. 22723121 Email ID: corp.relations@bseindia.com

Dear Sir,

Ref: Company Code No. 524768
Sub: Outcome of the Board Meeting.

Pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015, this is to inform you that the Board of Directors of the Company, at its meeting held today at 12.30 pm, have approved and taken on record the Un-Audited Financial Results of the Company for the quarter ended June 30, 2019.

We are attaching herewith the following for your records.

1. Un-Audited Financial Results for the quarter ended June 30, 2019.
2. Limited Review dated July 5, 2019.

The above results were reviewed by the audit committee of the Board of Directors. We are filing the results online in CASF and XBRL format. This is for your information and record.

Thanking you,

Yours faithfully,
For Emmessar Biotech & Nutrition Ltd



Compliance Officer
Attachment: As above.

Factory: Plot No. T-3/2, MIDC Area, P.O. Box No. 39. Talaja - 410208. Dist. Raigad. Maharashtra.
Tel: 022-20870587 Email: enquiries@ebnl.org Web-Site: www.ebnl.org

EMMESSAR BIOTECH & NUTRITION LIMITED
 Regd Office: T-3/2, MIDC, Taloja, Raigad District, Maharashtra State
 CIN: L24110MH1992PLC06594229

UNAUDITED FINANCIAL RESULTS (STANDLONE) FOR THE QUARTER ENDED 30TH JUNE 2019

Sr. No	Particulars	(Rupees in Lakhs)			
		Quarter Ended			Year Ended
		30.06.2019 Unaudited	31.03.2019 Audited	30.06.2018 Audited	31.03.2019 Audited
PART A					
1	Revenue from Operations	188.56	15.27	13.85	62.95
2	Other Income	35.37	35.86	31.02	129.99
	Total Income (1 + 2) A	223.93	51.13	44.87	192.94
PART B					
3	Expenses				
	Cost of material consumed	62.97	39.55	1.80	36.60
	Purchase of Stock-trade	12.45	0.45	4.50	17.95
	Change in Inventories of Finished goods	33.83	-46.05	-1.40	-42.14
	Employee Benefit Expenses	13.63	10.56	10.58	57.55
	Depreciation & Amortisation of Assets	1.45	1.40	2.15	7.86
	Other Expenditure	59.63	26.76	9.48	57.07
	Total Expenses B	183.96	32.67	27.11	134.89
4	Profit / (loss) from Operations before exceptional items & Tax (A-B)	39.97	18.46	17.76	58.05
5	Exceptional items	0.00	28.67	0.00	28.67
6	Profit / (loss) before tax (4 - 5)	39.97	-10.21	17.76	29.38
7	Tax Expenses				
	1. Current Tax (MAT)	0.00	-6.00	0.00	-6.00
	2. Deferred Tax	0.00	1.91	0.00	1.91
	3. MAT Credit available	0.00	28.00	0.00	28.00
8	Net Profit / (loss) after tax (6 - 7)	39.97	13.70	17.76	53.29
9	Other Comprehensive Income	0.00	-0.96	0.00	-0.96
10	Total comprehensive income and Other Comprehensive Income	39.97	12.74	17.76	52.33
11	Paid-up Equity Share Capital (Face Value of the share)	499.61 10.00	499.61 10.00	499.61 10.00	499.61 10.00
	Earning per Shares				
	1. Basic	0.80	0.25	0.36	1.05
	2. Diluted	0.80	0.25	0.36	1.05

Notes:

- The above results were taken on record by the Board of Directors and the Audit Committee at their meeting held on 5th July 2019 and have been subjected to Limited Review by the Statutory Auditors. The review report of the Statutory Auditors is being filed with the BSE.
- The Company operates three segments ie. Healthcare, Fine Chemicals and rent on leasehold land during this quarter.
- Deferred tax & provision for taxation will be calculated annually.
- No Investor Compliant was received for the quarter ended 30th June 2019



Mumbai
05-Jul-19

MSR Ayyangar
Managing Director



EMMESSAR BIOTECH & NUTRITION LIMITED

Regd Office: T-3/2, MIDC, Taloja, Raigad District, Maharashtra State

CIN: L24110MH1992PLC06594229

Segmentwise Revenue, Results and Capital Employed for the Quarter Ended 30th June 2019

[Rs. In Lakhs]

		Quarter Ended				Year Ended
		30.06.2019	31.03.2019	30.06.2018	31.03.2019	
		Unaudited	Audited	Audited	Audited	
1	1. Segment Revenue					
a	Healthcare	41.96	3.72	13.85	51.4	
b	Fine Chemicals	146.60	11.55	0.00	11.55	
c	Rent on Leasehold Land	33.78	33.78	30.71	125.92	
d	Others	1.59	2.08	0.31	4.08	
	Total:	223.93	51.13	44.87	192.95	
	Less: Inter Segment Revenue	0	0.00	0.00	0	
	Net Sales / Income from Operations	223.93	51.13	44.87	192.94	
2	2 Segment Results (Profit / Loss) tax					
a	Healthcare	26.72	1.14	8.47	29.21	
b	Fine Chemicals	7.38	0.32	0.00	0.32	
c	Rent on Leasehold Land	33.55	33.78	30.48	125.92	
d	Others	1.59	2.08	0.31	4.08	
	Total:	69.24	37.32	39.26	159.53	
	Less:					
	Interest	0	0.00	0.00	0	
	Other Unallocable Expenditure (Net off)	29.27	18.86	21.50	101.48	
	Total Profit before Tax	39.97	18.46	17.76	58.05	
3	3 Capital Employed (Segment Assets - Segment Liabilities)					
a	Healthcare	7.87	7.97	12.41	7.97	
b	Fine Chemicals	71.73	71.51	64.13	71.51	
c	Leasehold Land	2.78	3.01	3.72	3.01	
d	Others	172.84	179.41	190.24	179.41	
	Total:	255.22	261.90	270.50	261.90	

Note: The Fixed Assets are employed for the general enterprise and are not segmental in nature.

The above results were taken on record at a meeting of the Board of Directors held on July 5th, 2019

Mumbai
05-Jul-19

By order of the Board
MSR Ayyangar
Managing Director




Tel. : 2200 4465, 2206 7440
Fax : 91-22-2200 0649
E-mail : mumbai@vsa.co.in
Website : www.vsa.co.in

V. Sankar Aiyar & Co.

CHARTERED ACCOUNTANTS
2-C, Court Chambers
35, New Marine Lines
Mumbai - 400 020

**LIMITED REVIEW REPORT ON THE UNAUDITED FINANCIAL RESULTS
FOR THE HALF YEAR ENDED 30th JUNE 2019.**

The Board of Directors
Emmessar Biotech & Nutrition Limited

1. We have reviewed the accompanying statement of unaudited financial results of Emmessar Biotech & Nutrition Limited ("the Company") for the quarter ended 30th June, 2019 (the Statement) being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Circular No. CIT/CFD/FAC/62/2016 dated 5th July 2016. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the applicable Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Agreement and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No: CIR/CFD/FAC/62/2016 dated July 5, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Mumbai
Date: July 5th, 2019

For V. Sankar Aiyar & Co.
Chartered Accountants
Firm Regn. No.109208W



(V. Mohan)
Partner
Membership No.17748
UDIN: 19017748AAAAAX4995